Aslepios Bioresearch chief scientific adviser Frank Sams-Dodd writes about the relative merits of disease-based and target-based drug discovery in the context of an expensive and tough development environment. A disease-based approach may appear less cost-effective, but that changes if the costs are compared on a per-mechanism-tested basis, he writes.